Day: September 8, 2025

First-line camizestrant for ESR-1 mutated advanced breast cancer

SERENA-6 trial shows a longer progression-free survivAal with camizestrant added to a CDK4/6 inhibitor in advanced breast cancer with an ESR-1 mutation emerged during treatment